Forward Pharma A/S (FWP.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Forward Pharma Says European Patent Office Has Revoked EP2801355 Patent
- BRIEF-Mark Lampert Reports 11.3 Percent Passive Stake In Forward Pharma A/S
- BRIEF-Forward Pharma Files Further Written Submissions In European Opposition Proceeding For EP2801355 Patent
- BRIEF-Forward Pharma announces completion of corporate restructuring plan
- BRIEF-Forward pharma says filing in U.S. Court to appeal PTAB decision